AstraZeneca- It is expected to be approved within a few months. The AstraZeneca vaccine is based on time-tested technology that employs a harmless cold virus (called adenovirus) that has been genetically modified to stimulate an immune response against the coronavirus.
It appears to be safer in the long term because it is not a mRNA vaccine. Compared to the other two, it is much cheaper($3-$4), has a much longer shelf life (6 months) and much higher storage temperature(36-46 degrees). The downside is it has a lower efficacy rate of 62-90%.
News 
Market Data 
Discover 
